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Abstract
Soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (four-event stack soybean) was
produced by conventional crossing to combine four single events: MON 87751, MON 87701, MON 87708
and MON 89788. The GMO Panel previously assessed the four single events and did not identify safety
concerns. No new data on the single events have been identified that would lead to modification of the
original conclusions on their safety. The molecular characterisation, comparative analysis (agronomic,
phenotypic and compositional characteristics) and the outcome of the toxicological and allergenicity
assessment indicate that the combination of the single soybean events and of the newly expressed
proteins in the four-event stack soybean does not give rise to food and feed safety and nutritional
concerns. The GMO Panel concludes that the four-event stack soybean, as described in this application,
is as safe as and nutritionally equivalent to the non-GM comparator and the non-GM reference varieties
tested. In the case of accidental release of viable seeds of the four-event stack soybean into the
environment, this would not raise environmental safety concerns. The post-market environmental
monitoring plan and reporting intervals are in line with the intended uses of the four-event stack
soybean. Post-market monitoring of food/feed is not considered necessary. The GMO Panel concludes
that the four-event stack soybean is as safe as the non-GM comparator and the tested non-GM reference
varieties with respect to potential effects on human and animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2016-128 under Regulation (EC) No 1829/2003
from Monsanto (hereafter referred to as ‘the applicant’), the Panel on Genetically Modified Organisms of
the European Food Safety Authority (hereafter referred to as the ‘GMO Panel’) was asked to deliver a
scientific opinion on genetically modified (GM) soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 (hereafter referred to as ‘the four-event stack soybean’). The scope of application
EFSA-GMO-NL-2016-128 is for the placing on the market of the four-event stack soybean for food and
feed uses, import and processing.
The four-event stack soybean was produced by conventional crossing to combine four single
soybean events: MON 87751 (expressing Cry1A.105 and Cry2Ab2), MON 87701 (expressing Cry1Ac),
MON 87708 (expressing DMO) and MON 89788 (CP4 EPSPS), to confer tolerance to dicamba- and
glyphosate-containing herbicides and resistance against specific lepidopteran pests.
The GMO Panel evaluated the four-event stack soybean with reference to the scope and
appropriate principles described in its guidelines for the risk assessment of GM plants and derived food
and feed, the environmental risk assessment of GM plants and the post-market environmental
monitoring (PMEM) of GM plants. The GMO Panel considered the information available on the single
events, the four-event stack soybean, the scientific comments submitted by the Member States and
the relevant scientific literature.
The single events MON 87751, MON 87701, MON 87708 and MON 89788 were previously assessed
by the European Food Safety Authority (EFSA) and no concerns on their safety were identified. No
new safety issue was identified by updated bioinformatic analyses, nor reported by the applicant
concerning the four single soybean events, since the publication of the respective scientific opinions.
Consequently, the GMO Panel considers that its previous conclusions on the safety of the single
soybean events remain valid.
For the four-event stack soybean, the risk assessment included the molecular characterisation of
the inserted DNA and analysis of protein expression. An evaluation of the comparative analysis of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the PMEM plan
was also undertaken.
The molecular characterisation data establish that the events stacked in the four-event stack
soybean have retained their integrity. Protein expression analyses show that the levels of the newly
expressed proteins are comparable in the four-event stack and in the single events. No indications of
interactions that may affect the integrity of the events and the levels of the newly expressed proteins
in this four-event stack soybean were identified.
The comparative analysis of forage and seed composition and agronomic/phenotypic characteristics
identified no differences between the four-event stack soybean and the non-GM comparator that
required further assessment for food/feed safety or environmental impact, except for the levels of Gly
m 4 protein in seeds. Those changes were further assessed and not found to have a safety impact.
The molecular characterisation, the comparative analysis and the outcome of the toxicological and
allergenicity assessment indicate that the combination of the single soybean events and of the newly
expressed proteins in the four-event stack soybean does not give rise to food and feed safety and
nutritional concerns. The GMO Panel concludes that soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788, as described in this application, is as safe as and nutritionally equivalent to the
non-GM comparator and the commercial non-GM soybean reference varieties (hereafter ‘non-GM
reference varieties’) tested.
Considering the combined events and their potential interactions, the outcome of the comparative
analysis and the routes and levels of exposure, the GMO Panel concludes that soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 would not raise safety concerns in the case of
accidental release of viable GM soybean seeds into the environment.
Given the absence of safety concerns for foods and feeds from the four-event stack soybean, the
GMO Panel considers that post-market monitoring of food/feed is not considered necessary. The PMEM
plan and reporting intervals are in line with the intended uses of the four-event stack soybean. The
literature searches did not identify any relevant publications on the four-event stack soybean. In the
context of annual PMEM reports, the applicant could further improve future literature searches
according to the GMO Panel recommendations provided in this scientific opinion.
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The GMO Panel concludes that soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788,
as described in this application, is as safe as the non-GM comparator and the tested non-GM reference
varieties with respect to potential effects on human and animal health and the environment.
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1. Introduction
The scope of application EFSA-GMO-NL-2016-128 is for food and feed uses, import and processing
in the European Union (EU) of the genetically modified (GM) insect resistant and herbicide tolerant
soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788.
1.1. Background
On 23 December 2015, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands the application EFSA-GMO-NL-2016-128 for authorisation of soybean
MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (Unique Identifier MON-87751-7 9 MON
877Ø1-2 9 MON-877Ø8-9 9 MON-89788-1), submitted by Monsanto (hereafter referred to as ‘the
applicant’) according to Regulation (EC) No 1829/2003.1
Following receipt of application EFSA-GMO-NL-2016-128, EFSA informed EU Member States and the
European Commission, and made the summary of the application available to the public on the EFSA
website.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC) No
1829/2003 and Regulation (EU) No 503/20133 and, when needed, asked the applicant to supplement
the initial application. On 22 August 2016, EFSA declared the application valid, and made the valid
application available to EU Member States and the European Commission.
From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter
referred to as the ‘GMO Panel’) endeavoured to respect a time limit of six months to issue a scientific
opinion on application EFSA-GMO-NL-2016-128. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC) No
1829/2003, any supplementary information provided by the applicant during the risk assessment was
made available to the EU Member States and European Commission (for further details, see the
section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU Member States, including national Competent Authorities within the meaning of Directive
2001/18/EC.4 The EU Member States had three months to make their opinion known on the
application EFSA-GMO-NL-2016-128 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientific risk assessment of soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 in the context of its scope as defined in application EFSA-GMO-NL-2016-128.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation, including the opinions of the nominated
risk assessment bodies of EU Member States.5
In addition to the present scientific opinion on soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788, EFSA and its GMO Panel were also asked to report on the particulars listed
under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003. The relevant information is made
available in the EFSA Register of Questions,6 including: the information required under Annex II to the
Cartagena Protocol, a labelling proposal and a post-market environmental Monitoring (PMEM) plan as
provided by the applicant; the method(s), validated by the Community reference laboratory, for
detection, including sampling and identification of the transformation event in the food-feed and/or
foods-feeds produced from it; and the appropriate reference materials.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online at the EFSA Register of Questions: http://registerofquestions.efsa.europa.eu/roqFrontend/login?0) querying the
assigned Question number.
3 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
5 Opinions of the nominated risk assessment bodies of EU Member States can be found at the EFSA Register of Questions
(http://registerofquestions.efsa.europa.eu/roqFrontend/login?0) querying the assigned Question number.
6 http://registerofquestions.efsa.europa.eu/roqFrontend/login?0 querying the assigned Question number.
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2. Data and methodologies
2.1. Data
The GMO Panel based its scientific risk assessment of soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 on the valid application EFSA-GMO-NL-2016-128, additional information provided
by the applicant during the risk assessment, scientific comments submitted by EU Member States and
relevant peer-reviewed scientific publications. As part of this comprehensive information package, the
GMO Panel received additional unpublished studies submitted by the applicant in order to comply with
the specific provisions of Regulation (EU) No 503/2013. A list of these additional unpublished studies is
provided in Appendix B.
2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU) No
503/2013, its applicable guidelines (EFSA GMO Panel, 2010a,b, 2011a,b, 2015), explanatory notes and
statements (EFSA, 2014, 2017a,b, 2019) for the risk assessment of GM plants. During its risk
assessment, the GMO Panel considered all additional unpublished studies as listed in Appendix B for
potential effects on human and animal health and the environment.
For the assessment of 90-day animal feeding studies, the GMO Panel took into account the criteria
included in the EFSA Scientific Committee guidance on conducting repeated-dose 90-day oral toxicity
study in rodents on whole food/feed (EFSA Scientific Committee, 2011) and the explanatory statement
for its applicability (EFSA, 2014).
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017a, 2019).
In the frame of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in performing
bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2016-128 covers the four-event stack soybean MON 87751 9
MON 87701 9 MON 87708 9 MON 89788. This four-event stack soybean was developed by
conventional crossing to combine four single events: MON 87751 (expressing the Cry1A.105 and
Cry2Ab2 proteins for protection against specific lepidopteran pests), MON 87701 (expressing the Cry1Ac
protein for resistance against specific lepidopteran pests), MON 87708 (expressing the DMO proteins for
tolerance to dicamba-containing herbicides) and MON 89788 (expressing the CP4 EPSPS protein for
tolerance to glyphosate-containing herbicides). It should be noted that the assessment of herbicide
residues relevant for this application has been investigated by the EFSA Pesticides Unit (EFSA, 2013,
2018a).
All four single events were assessed previously (see Table 1) and no concerns for human and
animal health or environmental safety were identified.
Table 1: Single soybean events assessed by the GMO Panel
Event Application or mandate EFSA Scientific Opinion
MON 87751 EFSA-GMO-NL-2014-121 EFSA GMO Panel (2018a)
MON 87701 EFSA-GMO-BE-2010-79 EFSA GMO Panel (2011b)
MON 87708 EFSA-GMO-NL-2011-93 EFSA GMO Panel (2013)
MON 89788 EFSA-GMO-NL-2006-36 EFSA (2008)
EFSA-GMO-RX-011 EFSA GMO Panel (2018b)
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3.2. Updated information on single events7,8
Since the publication of the scientific opinions on the single soybean events (see Table 1), no safety
issue concerning the four single events has been reported by the applicant.
Updated bioinformatic analyses for soybean events MON 87751, MON 87701, MON 87708 and MON
89788 confirmed that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed Cry1A.105,
Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins confirmed previous results indicating no significant
similarities to toxins and allergens. Updated bioinformatics analyses of the newly created Open Reading
Frames (ORFs) within the inserts or spanning the junctions between the insert and the flanking regions
for soybean events MON 87751, MON 87701, MON 87708 and MON 89788 confirmed previous analyses
(Table 1). These analyses indicate that the production of a new peptide showing significant similarities to
toxins or allergens for any of the events in soybean MON 87751 9 MON 87701 9 MON 87708 9 MON
89788 is highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis for soybean events MON 87751, MON
87701, MON 87708 and MON 89788 to microbial DNA. The likelihood and potential consequences of
plant-to-bacteria gene transfer are described in Section 3.7.2.1.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single soybean events remain valid.
3.3. Systematic literature review9
The GMO Panel assessed the applicant’s literature searches on soybean MON 87751 9 MON 87701 9
MON 87708 9 MON 89788, which include a scoping review, according to the guidelines given in EFSA
(2010, 2017a, 2019).
A systematic review as referred to in Regulation (EU) No 503/2013 has not been provided in
support to the risk assessment of the application EFSA-GMO-NL-2016-128. Based on the outcome of
the scoping review, the GMO Panel agrees that there is limited value of undertaking a systematic
review for soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 at present.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that future searches on soybean MON 87751 9 MON 87701 9 MON 87708 9
MON 89788 could be improved. The GMO Panel therefore recommends the applicant to:
• Ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientific terminology, common typos, translation issues);
• Ensure that enough truncation is used and that it is being used consistently;
• Include controlled vocabulary (subject indexing) in the searches when available, and where
subject headings are available, use both free-text terms and controlled vocabulary in the
searches.
The literature searches did not identify any relevant publications on soybean MON 87751 9
MON 87701 9 MON 87708 9 MON 89788.
3.4. Molecular characterisation
In line with the requirements laid down by Regulation (EU) 503/2013, the possible impact of the
combination of the events on their integrity, the expression levels of the newly expressed proteins or
the biological functions conferred by the individual inserts are considered below.
3.4.1. Genetic elements and their biological function7
Soybean events MON 87751, MON 87701, MON 87708 and MON 89788 were combined by
conventional crossing to produce the four-event stack soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788. The structure of the inserts introduced into the four-event stack soybean is
described in detail in the respective EFSA scientific opinions (Table 1) and no new genetic
7 Dossier: Part II – Section 1.2.2.2
8 Additional information: 13/8/2018 and 3/10/2018.
9 Dossier: Part II – Section 7; additional information: 20/7/2018.
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modifications were involved. Genetic elements in the expression cassettes of the single events are
summarised in Table 2.
Intended effects of the inserts in soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788
are summarised in Table 3.
Based on the known biological function of the newly expressed proteins (Table 3), the only
potential functional interactions at the biological level are between the three Cry proteins in susceptible
insects.
Table 2: Genetic elements in the expression cassettes of the events stacked in soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788
Event Promoter 50 UTR Transit peptide Coding region Terminator
MON 87751 act2 (A. thaliana)
rbcS4 (A. thaliana)
–
–
CTP2 (A. thaliana)
rbcS4 (A. thaliana)
cry2Ab2* (B.
thuringiensis)
cry1A.105* (B.
thuringiensis)
mt (O. sativa)
pt1 (M.
truncatula)
MON 87701 rbcS4 (A. thaliana) – CTP1 (A. thaliana) Cry1Ac* (B.
thuringiensis)
7Sa’ (Glycine
max)
MON 87708 PC1SV (Peanut
chlorotic streak
caulimovirus)
TEV (Tobacco
Etch virus)
rbcS (Pisum
sativum)
dmo
(Stenotrophomonas
maltophilia)
E9 (Pisum
sativum)
MON 89788 FMV/EF-1a (Figwort
Mosaic Virus and A.
thaliana)
L–EF-1a/I–EF-1a
(A. thaliana)
CTP2 (A. thaliana) cp4 epsps* (A.
tumefaciens CP4)
E9 (Pisum
sativum)
*: Codon optimised.
–: When no element was specifically introduced to optimise expression.
Table 3: Characteristics and intended effects of the events stacked in soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON 87751 Cry2Ab2
Cry1A.105
Based on genes from B. thuringiensis
subsp. kurstaki. B. thuringiensis is an
insect pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Widner and Whiteley,
1990)
Based on genes from B. thuringiensis. B.
thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Widner and Whiteley, 1990)
Event MON 87751 expresses the Cry2Ab2,
a protein toxic to certain lepidopteran
larvae feeding on soybean
Event MON 87751 expresses a modified
version of the Cry1A-type protein.
Cry1A.105 is a protein toxic to certain
lepidopteran larvae feeding on soybean
MON 87701 Cry1Ac Based on genes from B. thuringiensis
subsp. kurstaki HD-73. B. thuringiensis is
an insect pathogen; its insecticidal activity
is attributed to the expression of crystal
protein (cry) genes (Donovan et al., 1992)
Event MON 87701 expresses a chimeric,
truncated cry1Ac gene which was modified
to enhance its expression in plants. Cry1Ac
is a chimeric protein toxic to certain
lepidopteran larvae feeding on soybean
MON 87708 DMO Based on a gene from Stenotrophomonas
maltophilia strain DI-6. Dicamba mono-
oxygenase (DMO) is an enzyme that
catalyses the demethylation of dicamba to
the non-herbicidal compound 3,6-
dichlorosalicylic acid and formaldehyde
(Herman et al., 2005)
Event MON 87708 expresses DMO protein
which degrades the herbicide dicamba and
thus confers tolerance to this herbicide
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3.4.2. Integrity of the events in the four-event stack10
The genetic stability of the inserted DNA over multiple generations in the single soybean events
MON 87751, MON 87701, MON 87708 and MON 89788 was demonstrated previously (see Table 1).
Integrity of these genetically independent events in soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 was demonstrated by polymerase chain reaction (PCR) and sequence analysis,
which show that the sequences of the events (inserts and their flanking regions) in the four-event
stack soybean are identical to the sequences originally reported for the four single events.
3.4.3. Information on the expression of the inserts11,12
Cry2Ab2, Cry1A.105, Cry1Ac, DMO and CP4 EPSPS protein levels were analysed by enzyme-linked
immunosorbent assay (ELISA) in material harvested from a field trial at five locations in the USA in
2013. Samples analysed included over season leaf (OSL1-4), root (R6), forage (R6) and seed (R8)
treated with intended herbicides. In order to assess the changes in protein expression levels which
may result from potential interactions between the events, protein levels were determined for the four-
event stack soybean and the corresponding single events in different parts of the plant.
The levels of all the newly expressed proteins in the four-event stack soybean were comparable to
those of the single events (Appendix A). Therefore, there is no indication of an interaction that may
affect the levels of the newly expressed proteins in this stack.
3.4.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788 have retained their integrity. Protein expression analyses showed
that the levels of the newly expressed proteins are comparable in the four-event stack and in the
single events. Therefore, there is no indication of an interaction that may affect the integrity of the
events or the levels of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, the only potential
functional interactions are between the three Cry proteins in susceptible insects, which will be
addressed in Section 3.7.
3.5. Comparative analysis13
3.5.1. Overview of studies conducted for the comparative analysis
Application EFSA-GMO-NL-2016-128 presents data on agronomic and phenotypic characteristics as
well as on forage and seed composition of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON
89788 (Table 4).
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON 89788 CP4 EPSPS Based on a gene from Agrobacterium
strain CP4 (Barry et al., 2001). 5-
enolpyruvyl-shikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic
amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event MON 89788 expresses the bacterial
CP4 EPSPS protein which confers tolerance
to glyphosate-containing herbicides as it
has lower affinity towards glyphosate than
the plant endogenous enzyme
10 Dossier: Part II – Section 1.2.2.2.a and additional study MSL0026332.
11 Dossier: Part II – Section 1.2.2.3 and additional study MSL0027230.
12 Additional information: 14/11/2018, 25/2/2019 and 8/5/2019.
13 Dossier: Part II – Section 1.3; additional information: 13/8/2018 and 29/1/2019.
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3.5.2. Experimental field trial design and statistical analysis
At each field trial site, the following materials were grown: soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788, the comparator soybean A3555 and four non-GM reference
varieties. All materials were treated with conventional herbicides management regimes; in addition, the
field trials included soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 exposed to the
intended dicamba- and glyphosate-containing herbicides on top of the conventional herbicides.
The agronomic/phenotypic and compositional data were analysed as specified by EFSA GMO
Panel (2010b, 2011a). This includes, for each of the two treatments of soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788, the application of a difference test (between the GM soybean
and its comparator) and an equivalence test (between the GM soybean and the set of non-GM
reference varieties).14 The results of the equivalence test are categorised into four possible outcomes
(I–IV, ranging from equivalence to non-equivalence).15
3.5.3. Suitability of selected test materials
3.5.3.1. Selection of the GM soybean line and comparator
To obtain the four-event stack GM soybean, the single event MON 87751 and the three-event stack
MON 87701 9 MON 87708 9 MON 89788 were combined by conventional crossing in the non-GM
soybean varieties A3555 and A3525, respectively, before crossing.
The comparator used in the field trials is the non-GM soybean variety A3555, which has high
similarity with the soybean line A3525. As documented by the pedigree and by the additional
information, the EFSA GMO Panel considers the selected line (A3555) a suitable comparator for the
comparative analysis.
The GM soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and its comparator
A3555 both belong to the maturity group 3.5 that is appropriate for growing in a range of
environments across North America.
3.5.3.2. Selection of commercial non-GM soybean reference varieties
Commercial non-GM soybean reference varieties with maturity groups ranging from 2.8 to 4.1 were
included in the field trials. Based on the information on the maturity groups, the GMO Panel considers
that the selected non-GM soybean reference varieties are appropriate for the comparative analysis.
Table 4: Overview of comparative analysis studies to characterise the four-event stack soybean in
application EFSA-GMO-NL-2016-128
Study focus Study details Comparator
Non-GM reference
varieties
Agronomic and phenotypic
characteristics
Field trials, 2013 and 2016,
US, 11 sites(a)
A3555 31(b)
Compositional analysis Field trials, 2013, US, 9 sites(a) 18(b)
(a): Eight field trials conducted in 2013 were used for both the compositional and the agronomic/phenotypic analysis: at Jackson
County, Arkansas; Jefferson County, Iowa; Champaign County, Illinois; Pawnee County, Kansas; Perquimans County, North
Carolina; Polk County, Nebraska; Miami County, Ohio; and Lehigh County, Pennsylvania. A field trial in Stark County, Illinois,
2013, was used only for compositional analysis. Four field trials conducted in 2016 were used only for the agronomic/
phenotypic analysis: at Jasper County, Iowa; Clinton County, Illinois; Clinton County, Indiana; and Lehigh County,
Pennsylvania (the latter was tested both in 2013 and in 2016).
(b): The following 18 varieties were used for both the compositional and the agronomic/phenotypic characterisation: A3244,
A3525, C3211N, C3884N, DWIGHT, eMerge 348TC, Garst 3585N, Hoffman H419, Hoffman HS387, Lewis 372, Maverick,
Midland 363, NE3202, NuPride 2954, Steward SB3454, Stine 3300-0, Wilken 3316 and WILLIAMS 82. In addition, the field
trials used for agronomic/phenotypic analysis included the following 13 varieties: Asgrow A3253, Asgrow A3956, Becks
331N, Becks 389N, Great Lakes GL3029, ILLINI 2880A, ILLINI 3477N, ILLINI 3880B, ILLINI 6336N, Legend Seeds LS
2880NHP, Stine 3120-2, Stine 3520-2 and Stine 3900-2.
14 The purpose of the test of equivalence is to evaluate the estimated mean values for the stack GM crop taking into account
natural variability as defined by a set of non-GM reference varieties with a history of safe use for consumption as food or feed.
15 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
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3.5.3.3. Seed production and quality
The seeds of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and the comparator
used in the field trials (see Table 4) were produced, harvested and stored under similar conditions before
being sown. The seed lots were verified for their purity via event specific quantitative PCR analysis. The
mean germination rates of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and the
non-GM comparator were 99% and 99%, respectively (seed lots used in the 2013 field trials) and 99%
and 98%, respectively (seed lots used in the 2016 field trials). The GMO Panel considers that the starting
seed used as test material in the agronomic, phenotypic and compositional studies was of suitable
quality.
3.5.3.4. Conclusion on suitability
The GMO Panel is of the opinion that the soybean MON 87751 9 MON 87701 9 MON 87708 9 MON
89788, its comparator and the non-GM soybean reference varieties were properly selected and are of
acceptable quality. Therefore, the test materials are considered suitable for the comparative analysis.
3.5.4. Representativeness of the receiving environments
3.5.4.1. Selection of field trial sites
The selected field trial sites were located in commercial soybean-growing regions of North America.
The soil characteristics of the selected fields were diverse,16 corresponding to optimal, near-optimal and
suboptimal conditions for soybean cultivation (Sys et al., 1993). The GMO Panel considers that the
selected sites reflect commercial soybean-growing regions in which the test materials are likely to be
grown.
3.5.4.2. Meteorological conditions
Maximum and minimum mean temperatures and sum of precipitations were provided on a monthly
basis. No exceptional weather conditions were reported at any of the selected field trial sites. The
GMO Panel considers that the meteorological data set falls within the range of climatic conditions
normally occurring at these sites.
3.5.4.3. Management practices
The field trial included plots containing the four-event stack soybean, plots with the comparator
and plots with non-GM reference varieties, all managed according to local agricultural practices. In
addition, the field trials included plots containing the four-event stack soybean managed following the
same agricultural practices, plus exposed to the intended herbicides. Dicamba- containing herbicide
was applied at the V2-V5 growth stage and glyphosate-containing herbicide at V4-R1 growth stage.
The GMO Panel considers that the management practices including planting, harvesting and application
of plant protection products were appropriate.
3.5.4.4. Conclusion on representativeness
The GMO Panel concludes that the geographical locations, soil characteristics, meteorological
conditions and management practices of the field trials are typical for receiving environments where
the tested materials could be grown.
3.5.5. Agronomic and phenotypic analysis
Nine agronomic and phenotypic endpoints17 plus information on abiotic stressors, disease incidence
and arthropod damage were evaluated in the field trials (see Table 4). The endpoint pod shattering
was not analysed with formal statistical methods because of lack of variability in the data. The
remaining eight endpoints were analysed with the tests of difference and equivalence, with the
following results:
16 Soil types of the field trials were silty clay loam, loam, silt loam, loam and sandy loam; soil organic carbon ranged from 0.9% to
6.5%.
17 Early stand count, days to 50% flowering, plant lodging, plant height, pod shattering, final stand count, seed moisture, 100
seed weight and yield.
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• For soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (treated and not treated),
statistically significant differences with the non-GM comparator were identified for two endpoints
(100 seed weight and seed moisture), which fell under equivalence category I or II.
3.5.6. Compositional analysis
Soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 seeds and forage harvested
from the field trials in 2013 (Table 4) were analysed for 74 different constituents (7 in forage and 67 in
seeds), including the key constituents recommended by the OECD (OECD, 2012). For 14 fatty acids in
seed,18 more than 50% of the observations were below the limit of quantification. The statistical
analysis was applied to the remaining 60 constituents (7 in forage19 and 53 in seed20); a summary of
the outcome of the test of difference and the test of equivalence is presented in Table 5.
• For soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (not treated), statistically
significant differences with the non-GM comparator were identified for 25 endpoints (one in
forage and 24 in seed) which all fell under equivalence category I or II except for Gly m 4 levels
in seed (Table 6).
• For soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (treated), significant
differences with the non-GM comparator were identified for 17 endpoints (one in forage and
16 in seed) which all fell under equivalence category I or II.
Table 5: Outcome of the comparative compositional analysis of soybean MON 87751 9 MON 87701 9
MON 87708 9 MON 89788. The table shows the number of endpoints in each category
Test of difference(a)
Not treated(c) Treated(c)
Not
different
Significantly
different
Not
different
Significantly
different
Test of
equivalence(b)
Category I/II 34 24(d) 42 17(d)
Category III/IV – 1(e) – –
Not categorised 1(f) 0 1(f) 0
Total endpoints 60 60
(a): Comparison between soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and its non-GM comparator.
(b): Four different outcomes: category I (indicating equivalence to the non-GM reference varieties); category II (equivalence is
more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not treated with intended herbicides: dicamba and glyphosate (see Section 3.5.4.3).
(d): Endpoints with significant differences between soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and its non-
GM comparator falling in equivalence category I-II. In forage, for both treated and not treated GM: protein. In seed, for both
treated and not treated GM: Gly m Bd 30k, glycine, stachyose, palmitic acid (16:0), oleic acid (18:1), linoleic acid (18:2),
linolenic acid (18:3), daidzein, genistein, carbohydrates, moisture, total fat and vitamin E; for the non-treated GM only:
arginine, isoleucine, leucine, methionine, phenylalanine, proline, threonine, valine, calcium, ash; for the treated GM only: Gly m
4, glutamic acid and serine.
(e): Gly m 4 level in seed was significantly different between soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788
(not treated) and its non-GM comparator and fell under equivalence category III. Quantitative results for this endpoint are
reported in Table 6.
(f): Endpoints not categorised for equivalence and without significant differences between the four-event stack soybean (both
treated and not treated) and its non-GM comparator: Gly m 1 in seed.
18 Caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid (14:0), myristoleic acid (14:1), pentadecanoic acid
(15:0), pentadecenoic acid (15:1), palmitoleic acid (16:1), heptadecanoic acid (17:0), heptadecenoic acid (17:1), c-linolenic
acid (18:3), eicosadienoic acid (20:2), eicosatrienoic acid (20:3) and arachidonic acid (20:4).
19 Crude protein, crude fat, ash, moisture, carbohydrates by calculation, acid detergent fibre (ADF) and neutral detergent fibre
(NDF).
20 Ash, carbohydrates, moisture, protein, total fat, acid detergent fibre (ADF), neutral detergent fibre (NDF), calcium,
phosphorus, alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, palmitic acid (16:0), stearic acid (18:0), oleic acid
(18:1), linoleic acid (18:2), linolenic acid (18:3), arachidic acid (20:0), eicosenoic acid (20:1), behenic acid (22:0), vitamin E,
vitamin K1, 2S albumin, Gly m 1, Gly m 3, Gly m 4, Gly m Bd 28k, Gly m Bd 30k, glycinin, ß-conglycinin, phytic acid, raffinose,
soybean lectin, stachyose, trypsin inhibitor, daidzein, genistein and glycitein.
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The GMO Panel assessed all significant differences between soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788 and the non-GM comparator, taking into account potential impact
on plant metabolism and the natural variability observed for the set of non-GM reference varieties.
Quantitative results for the endpoint showing significant differences between soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 and the non-GM comparator and falling under
equivalence category III are given in Table 6.
3.5.7. Conclusion of the comparative analysis
Taking into account the natural variability observed for the set of non-GM reference varieties, the
GMO Panel concludes that:
• None of the differences identified in the agronomic and phenotypic characteristics tested
between soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and the non-GM
comparator needs further assessment regarding their potential environmental impact.
• None of the compositional differences identified between soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788 and the non-GM comparator needs further assessment for
food/feed safety except for Gly m 4 levels in seed, which are further discussed in Section 3.6.4.2.
3.6. Food/feed safety assessment
3.6.1. Effects of processing
Soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 will undergo existing production
processes used for conventional soybean. Considering the changes observed in the compositional
comparative analysis (Section 3.5.6), the processing of the four-event stack soybean into food and
feed products is not expected to result in products being different from those of conventional non-GM
soybean varieties.
3.6.2. Influence of temperature and pH on newly expressed proteins
Effects of temperature and pH on newly expressed proteins Cry1A.105, Cry2Ab2, Cry1Ac, DMO and
CP4 EPSPS have been previously evaluated by the GMO Panel (Table 1). Additional studies on the effects
of heat treatment provided for DMO and Cry1Ac were assessed by the GMO panel (Appendix B).
3.6.3. Toxicology
3.6.3.1. Testing of newly expressed proteins
Five proteins (Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS) are newly expressed in soybean
MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (Section 3.4.1). The GMO Panel has
previously assessed these proteins in the context of the single events (Table 1), and no safety
concerns were identified for humans and animals. The unpublished toxicological studies provided in
the context of this application (see Appendix B) did not change this conclusion. The GMO Panel is not
aware of any other new information that would change this conclusion.
Table 6: Quantitative results (estimated means and equivalence limits) for the seed endpoint with
significant differences between soybean MON 87751 9 MON 87701 9 MON 87708 9 MON
89788 and its non-GM comparator, falling under category III in the test of equivalence
Endpoint
Soybean MON 87751 3 MON
87701 3 MON 87708 3 MON
89788
Non-GM
comparator
Non-GM reference varieties
Not treated Treated(a) Mean Equivalence limits
Gly m 4 (lg/g fw) 82.51* 92.18* 108.47 133.74 (89.90, 177.58)
fw: fresh weight.
(a): Treated with dicamba- and glyphosate-containing herbicides as described in Section 3.5.4.3.
For soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788, significantly different values are marked with an asterisk,
while the outcomes of the test of equivalence are differentiated by greyscale backgrounds: white (equivalence category II) and
light grey (equivalence category III).
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The potential for a functional interaction between the proteins newly expressed in soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 has been assessed with regard to human and
animal health. The three insecticidal proteins (Cry1A.105, and Cry2Ab2 and Cry1Ac) are delta-
endotoxins acting through cellular receptors found in target insect species. It is reported that the
gastrointestinal tract of mammals, including humans, lacks receptors with high specific affinity to Cry
proteins (Hammond et al., 2013; Koch et al., 2015). The DMO and CP4 EPSPS proteins are enzymes
that catalyse distinct biochemical reactions and act on unrelated substrates with high substrate
specificity.
On the basis of the known biological function of the individual newly expressed proteins (Table 3),
there is currently no expectation for possible interactions relevant to the food and feed safety of
soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788.
In vitro protein degradation studies on Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins
have been previously evaluated by the EFSA GMO Panel and no indications of safety concerns were
identified (Table 1).
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS in soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788.
3.6.3.2. Testing of new constituents other than newly expressed proteins
No new constituents other than newly expressed proteins have been identified in soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788. Therefore, no further food and feed safety
assessment of components other than the newly expressed proteins is required.
3.6.3.3. Information on altered levels of food and feed constituents
Gly m 4 levels in seed were significantly different in soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 when compared with its non-GM comparator and showed a lack of equivalence
with the non-GM reference varieties (Section 3.5.6). No toxicological concern is identified regarding
this compositional change. Further information on safety is provided in Section 3.6.4.2.
3.6.3.4. Testing of the whole genetically modified food and feed
Based on the outcome of the molecular characterisation, comparative analysis and toxicological
assessment, no indication of findings relevant to food/feed safety related to the stability and
expression of the inserts or to interaction between the transformation events, and no modifications of
toxicological concern in the composition of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON
89788 have been identified (see Sections 3.4.4, 3.5.7 and 3.6.3.3). Therefore, animal studies on food/
feed derived from soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 are not necessary
(EFSA GMO Panel, 2011a).
In accordance to Regulation (EU) No 503/2013, the applicant provided a 90-day oral repeated-dose
toxicity study in rats on whole food and feed from each of the single-event soybean MON 87751, MON
87701, MON87708 and MON89788. The four studies had already been provided in the context of the
single-event applications and assessed by the GMO Panel (Table 1); no adverse effects related to the
administration of the respective GM diets had been identified. In the context of the assessment of
soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 and in order to fulfil the
requirements of Regulation (EU) No 503/2013 for 90-day studies, upon EFSA’s request, the applicant
provided additional information on the 90-day studies on the whole food and feed from MON 87708
and MON87701 and a new study on the whole food and feed from MON 89788.
The GMO Panel has previously assessed the above-mentioned additional information on MON 87708
and the new study on MON 89788 in the context of another application under Regulation (EU) 503/
2013 (EFSA GMO Panel, 2019a). The additional histopathology21 provided for the 90-day study on the
whole food and feed from MON 87701 showed only sporadic histopathological findings compatible with
the spontaneous background pathology of rats of this strain and age.
On the basis of the additional information received, the GMO Panel concludes that all the above-
mentioned studies are in line with the requirements of Regulation (EU) 503/2013 and that there are no
21 Aorta, bone (sternum) with bone marrow, caecum, eyes with optic nerves, lungs, mandibular lymph node, mammary gland
(females only), oesophagus, pituitary, prostate, salivary gland, seminal vesicles, skeletal muscle, skin, trachea, urinary bladder,
vagina and Peyer’s Patches from all animals given the control and 30% test diet.
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indications of adverse effects related to the 90-day administration to rats of diets including up to 30%
seeds from soybean MON87751, MON87701, MON87708 and MON 897988.
3.6.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a; Commission Regulation (EU) No 503/2013). In addition, when known functional
aspects of the newly expressed protein or structural similarity to known adjuvants may indicate an
adjuvant activity, the possible role of these proteins as adjuvants is considered. When newly expressed
proteins with a potential adjuvant activity are expressed together, possible interactions increasing
adjuvanticity and impacting the allergenicity of the GM crop are assessed. Furthermore, an assessment
of specific newly expressed proteins in relation to their potential to cause coeliac disease was also
performed (EFSA GMO Panel, 2017).
3.6.4.1. Assessment of allergenicity of newly expressed proteins
For allergenicity, the GMO Panel has previously evaluated the safety of Cry1A.105, Cry2Ab2,
Cry1Ac, DMO and CP4 EPSPS proteins individually, and no concerns on allergenicity were identified in
the context of the applications assessed (Table 1). EFSA has recently published a technical report on
the safety assessment of genetically modified crops with Cry1Ac confirming previous EFSA opinions
(EFSA et al., 2018b). No new information on allergenicity of the proteins newly expressed in this four-
event stack soybean that might change the previous conclusions of the GMO Panel has become
available. Based on the current knowledge, and as none of the newly expressed proteins showed
allergenicity, no reasons for concerns on allergenicity regarding the simultaneous presence of these
newly expressed proteins in the four-event stack soybean affecting their allergenicity are expected.
For adjuvanticity, the Bt protein Cry1Ac has been suggested to possess adjuvant activity based on
animal studies when applied at relatively high doses (e.g. Vazquez et al., 1999; Santos-Vigil et al.,
2018). The Panel has previously evaluated the safety of Cry1A.105, Cry2Ab2 and Cry1Ac proteins, and
no concerns on adjuvanticity were identified in the context of the applications assessed (see Table 1).
More recently, this aspect has been discussed in detail by EFSA (EFSA et al., 2018b; Parenti et al.,
2019). The levels of the individual Bt proteins in the four-event stack soybean are comparable to those
in the respective single soybean events (see Section 3.4.3). From the limited experimental evidence
available, the GMO Panel did not find indications that the Bt proteins at the levels expressed in this
four-event stack soybean might act as adjuvants with the potential to enhance a specific
immunoglobulin E (IgE) response and to favour the development of an allergic reaction.
The applicant provided spontaneous information on the safety of the Cry1A.105, Cry2Ab2 and
Cry1Ac proteins regarding their potential hazard to cause a coeliac disease response.22 ,23 For such
assessment, the applicant followed the principles described in the EFSA GMO Panel guidance document
(EFSA GMO Panel, 2017). The assessment of the Cry2Ab2 and Cry1Ac identified no perfect or relevant
partial matches with known coeliac disease peptide sequences. The assessment of the Cry1A.105
revealed partial matches which have been previously evaluated by the GMO Panel (EFSA GMO Panel,
2019b). Therefore, no indications of safety concerns were identified by the GMO Panel.
3.6.4.2. Assessment of allergenicity of the GM plant products
Soybean is considered a common allergenic food24 (OECD, 2012). Therefore, any potential change
in the endogenous allergenicity of the GM plant should be assessed (Regulation (EU) No 503/2013).
For such assessment, the applicant included in the comparative analysis specific allergens relevant for
soybean (Section 3.5.6) measured by specific ELISA methods, which have been previously considered
acceptable (EFSA GMO Panel, 2010b; Fernandez et al., 2013; Selb et al., 2017). The applicant also
referred to the Kunitz trypsin inhibitor as a potential soybean allergen, which is an anti-nutrient and as
22 It is pointed out that the requirements laid down in the recent EFSA guidance on allergenicity (EFSA GMO Panel, 2017) are
not applicable to this dossier, as described in Section 1.5 ‘Transition period’ of the guidance document.
23 Additional information: 13/8/2018, 6/5/2019, 17/5/2019, 4/6/2019 and 7/8/2019.
24 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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such it is already assessed in the compositional analysis (Section 3.5.6). These allergens were selected
based on the list of potential soybean allergens described in the pertinent OECD document (OECD,
2012) and a scientific rational supporting their selection was provided by the applicant and considered
acceptable by the GMO Panel.
Allergen Gly m 4 levels in soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 (not
treated) were significantly different from those of the non-GM comparator and fell under equivalence
category III (see Section 3.5.6). For the assessment, the GMO Panel takes into account the fact that
the difference reported for this allergen consists in a decrease and that no relevant differences in the
content of other allergens were observed. Based on these considerations, no changes in the levels of
endogenous allergens raising concern are identified by the GMO Panel.
In the context of this application, the GMO Panel considers that there is no evidence that the
genetic modification might substantially change the overall allergenicity of the four-event stack
soybean when compared with that of the non-GM comparator and the non-GM reference varieties
tested.
3.6.5. Dietary exposure assessment to new constituents
In line with Regulation (EU) No 503/2013, the applicant provided dietary exposure estimates to
Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins newly expressed in soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788. Dietary exposure was estimated based on protein
expression levels reported in this application for the four-event stack soybean treated with the
intended herbicides, the current available consumption data and feed practices, the foods and feeds
currently available in the market and the described processing conditions.
Table 7 describes the protein expression levels used to estimate both human and animal dietary
exposure.
3.6.5.1. Human dietary exposure25
Human dietary exposure was estimated across different European countries on different population
groups: young population (infants, toddlers, ‘other children’), adolescents, adult population (adults,
elderly and very elderly) and special populations (pregnant and lactating women).
For the purpose of estimating dietary exposure, the levels of newly expressed proteins in MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 soybean were derived from replicated field trials in
the 2013 US growing season (five locations). Mean values (fresh weight basis) are considered as the
most adequate to estimate human dietary exposure (see Table 7). Since no specific consumption data
were available on commodities containing, consisting of or obtained from MON 87751 9 MON
87701 9 MON 87708 9 MON 89788 soybean, a conservative scenario with 100% replacement of
conventional soybean by the GM soybean was considered. Consumption figures for the relevant
commodities (soya bean flour, soya bread, textured soy protein, soya drink, soya-based infant formula,
soya-based follow-on formula, tofu, etc.) were retrieved from the EFSA Comprehensive European Food
Table 7: Mean values (n = 20, lg/g dry weight and lg/g fresh weight) for newly expressed
proteins in seeds and forage from soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 treated with a combination of the intended herbicides(a)
Protein
Tissue/developmental stage
Seeds/R8 (lg/g dry weight(b)
and lg/g fresh weight)
Forage/R6 (lg/g dry weight(b))
Cry1A.105 3.7/3.4 360
Cry2Ab2 2.7/2.5 5.6
Cry1Ac 7.7/7.0 100
DMO 13/12.0 18
CP4 EPSPS 100/92 270
(a): Intended herbicides: dicamba and glyphosate.
(b): Dry weight values used to estimate animal dietary exposure were calculated by dividing the values on a fresh weight basis
by the dry weight conversion factor obtained from moisture analysis data.
25 Dossier: Part II – Section 2.4.
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Consumption Database (EFSA consumption database).26 Soybean oil was excluded from the
assessment since no proteins are expected to be present in the oil.
For the acute dietary exposure estimations, the applicant estimated the relative amount of each of
the newly expressed proteins per gram of soybean protein and multiplied this value by the amount of
soybean protein consumed from soybean processed foods. The protein content of the relevant
processed foods was derived from the USDA National Nutrient Database,27 and the consumption data
were retrieved from the summary statistics of the EFSA consumption database.28 This is a conservative
approach as neither recipes nor the effect of processing on the final concentration of newly expressed
proteins are considered. Acute dietary exposure in high consumers within each dietary survey and age
class was estimated by using the food commodity with the highest acute consumption among
consumers only (95th or 97.5th percentile depending on the number of consumers). Table 8 shows the
highest acute dietary exposure for the different newly expressed proteins; dietary exposure estimates
were highest for CP4 EPSPS protein with 270.4 lg/kg body weight (bw) per day and 784.9 lg/kg bw
per day in ‘other children’ and adults, respectively. Most relevant food commodities in terms of
contribution to the exposure were soya drink and meat imitates (textured soy protein).
The GMO Panel estimated chronic dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4
EPSPS proteins. Individual consumption data of the relevant food commodities were retrieved from the
EFSA Consumption Database, using dietary surveys with at least 2 days consumption and covering a
total of 22 European countries.29 Different recipes and factors were considered to estimate the amount
of soybean in the consumed commodities before assigning Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4
EPSPS protein levels to the relevant commodities.30 No losses in the newly expressed proteins during
processing were considered. The 95th percentile chronic exposure (highly exposed population) was
derived from the distribution of the individual dietary exposure estimates within each dietary survey
and age class.
Table 9 shows the highest chronic dietary exposure to each of the newly expressed proteins across
European dietary surveys; highest dietary exposure ranged between 0.01 lg/kg bw per day for
Cry1A.105 and Cry2Ab2 proteins in infants (< 1 year old) and 73.1 lg/kg bw per day for CP4 EPSPS
protein in adolescents (≥ 10 years to < 18 years old). Main average contributors to the exposure in the
dietary surveys with the highest estimates were soybean flour in adolescents, and soya drink and soya
yoghurt in toddlers. In a scenario where ‘consumers only’ are considered, the highest dietary exposure
estimates in high consumers were 524.4 lg/kg bw per day and 48.1 lg/kg bw per day, for CP4 EPSPS
and DMO, respectively.
Table 8: Highest acute dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS
proteins (lg/kg bw per day) estimated across European dietary surveys and different age
classes
Acute dietary exposure (lg/kg bw per day)
Cry1A.105 Cry2Ab2 Cry1Ac DMO CP4 EPSPS
Other children 10.0 7.3 20.6 35.3 270.4
Adults 29.0 21.3 59.7 102.4 784.9
bw: body weight.
26 http://www.efsa.europa.eu/en/data/food-consumption-data
27 USDA, 2013. U.S. Department of Agriculture, Agricultural Research Service. 2013. USDA National Nutrient Database for
Standard Reference, Release 25. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl.
28 Summary statistics from the EFSA Comprehensive European Food Consumption Database accessed in July 2015.
29 Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Denmark, Estonia, Finland, France, United Kingdom, Greece,
Croatia, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Spain, Romania and Sweden.
30 Example: 100 g of tofu are made with approximately 26 g of soybeans; this would result in 23.9 µg of CP4 EPSPS per gram of
tofu as compared to 92 µg/g in the soybeans.
Assessment of soybean MON 87751 3 MON 87701 3 MON 87708 3 MON 89788
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2019;17(11):5847
An ad hoc dietary exposure scenario was carried out considering the consumption of protein-based
supplements (‘Protein and amino acids supplements’ and ‘Protein and protein components for sports
people’), under the assumption that these supplements are prepared from soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788. Consumption data on protein-based supplements
were available for a total of 14 European countries.2 The highest average acute dietary exposures
(consuming days only) ranged between 27.2 lg/kg bw per day for Cry2Ab2 and 1002.0 lg/kg bw per
day for CP4 EPSPS in adults. For high consumers (95th percentile exposure), the highest estimated
acute exposures ranged between 40.6 lg/kg bw per day for Cry2Ab2 and 1,495.4 lg/kg bw per day
for CP4 EPSPS, also in adults. Similarly, for chronic dietary exposure (consumers only), the highest
average estimates ranged between 17.3 lg/kg bw per day for Cry2Ab2 and 637.6 lg/kg bw per day
for CP4 EPSPS in adults. Only in one dietary survey, among those reporting consumption of protein-
based supplements, was the number of consumers higher than 60 to allow deriving a statistically
robust 95th percentile exposure representative of high consumers. The estimated exposure ranged
between 0.9 lg/kg bw per day for Cry2Ab2 and 31.5 lg/kg bw per day for CP4 EPSPS in ‘other
children’.
Furthermore, the consumption data on ‘Pollen supplements’ reported in the EFSA Consumption
Database27 indicates that additional dietary exposure to the newly expressed proteins can occur under
the assumption that these supplements contain pollen from soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788. Since no data on the presence of newly expressed proteins in
pollen were available, dietary exposure from this source was not estimated.
3.6.5.2. Animal dietary exposure25
Animal dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins was
estimated following the consumption of soybean meal and soybean forage/silage since these are the
two soybean products entering the feed chain. A conservative scenario with 100% replacement of
conventional soybean products by the GM products was considered.
Mean levels of Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins in soybean seeds and
forage/silage were derived from replicated field trial sites (five locations) in the 2013 US growing
season (Table 4). To estimate the mean NEP levels in soybean meal, a factor of 1.28-fold was applied
based on the protein content of soybean meal relative to soybean seed (OECD, 2012), assuming that
no losses of NEP occur during processing.
Dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins in soybean
MON87751 9 MON87701 9 MON87708 9 MON89788 following the consumption of soybean meal was
provided by the applicant across different animal species (i.e. broiler, finishing swine and dairy cattle),
based on estimates for animal body weight, daily feed intake and inclusion rates (percentage) of soybean
meal in animal diets (OECD, 2009). Estimated dietary exposure in livestock is reported in Table 10.
Table 9: Highest chronic dietary exposure estimates (95th percentile, highly exposed population) to
Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins (lg/kg bw per day) across
European dietary surveys and different age classes
Chronic dietary exposure (lg/kg bw per day)
N Cry1A.105 Cry2Ab2 Cry1Ac DMO CP4 EPSPS
Infants 11 0.01 0.01 0.02 0.03 0.2
Toddlers 14 1.7 1.3 3.5 6.0 46.2
Other children 19 1.2 0.9 2.4 4.1 31.4
Adolescents 18 2.7 2.0 5.6 9.5 73.1
Adults 19 0.4 0.3 0.9 1.6 12.1
Elderly 18 0.6 0.4 1.2 2.0 15.3
Very elderly 14 0.1 0.1 0.2 0.4 3.0
Pregnant women 2 0.4 0.3 0.9 1.5 11.4
Lactating women 2 0.1 0.1 0.2 0.4 3.2
bw: body weight; N: number of dietary surveys.
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The GMO Panel estimated dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS
proteins in dairy cattle following the consumption of soybean forage/silage, based on estimates for
animal body weight and daily feed intake (OECD, 2009), and for inclusion rates of soybean forage/silage
in animal diets (OECD, 2012). Estimated dietary exposure in dairy cattle is reported in Table 11.
3.6.6. Nutritional assessment of endogenous constituents
The intended traits of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 are
herbicide tolerance and insect resistance, with no intention to alter nutritional parameters. None of the
compositional differences identified between soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 and the non-GM comparator (see Section 3.5.6) needs further nutritional
assessment.
3.6.7. Conclusion of the food and feed safety assessment
The newly expressed proteins Cry1A.105, Cry2Ab, Cry1Ac, DMO and CP4 EPSPS in the four-event
stack soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 do not raise safety concerns
for human and animal health. No interactions between these proteins relevant for food and feed safety
were identified. Similarly, the GMO Panel did not identify indications of safety concerns regarding
allergenicity or adjuvanticity related to the presence of the newly expressed proteins in soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788, or regarding the overall allergenicity of this four-
event stack soybean. Based on the outcome of the comparative assessment, the GMO Panel concludes
that the nutritional impact of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788-
derived food and feed is expected to be the same as those derived from the comparator and non-GM
commercial reference varieties. The GMO Panel concludes that four-event stack soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 as described in this application, is nutritionally
equivalent to and as safe as the comparator and the non-GM reference varieties tested.
3.7. Environmental risk assessment and monitoring plan31
Considering the scope of the application EFSA-GMO-NL-2016-128, which excludes cultivation, the
environmental risk assessment (ERA) of soybean MON 87751 9 MON 87701 9 MON 87708 9
MON 89788 mainly takes into account: (1) the exposure of microorganisms to recombinant DNA in the
gastrointestinal tract of animals fed GM material and of microorganisms present in environments exposed
to faecal material of these animals (manure and faeces); and (2) the accidental release into the
environment of viable soybean MON 877519MON 877019MON 877089MON 89788 seeds during
transportation and/or processing (EFSA GMO Panel, 2010a).
Table 10: Dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins (lg/kg
bw per day) in livestock
Dietary exposure (lg/kg bw per day)
Cry1A.105 Cry2Ab2 Cry1Ac DMO CP4 EPSPS
Broiler 133.7 97.5 278.2 469.8 3,614
Finishing swine 42.6 31.1 88.7 149.7 1,152
Dairy cattle 45.5 33.2 94.7 160 1,231
Table 11: Dietary exposure to Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS proteins (lg/kg
bw per day) in livestock
Dietary exposure (lg/kg bw per day)
Cry1A.105 Cry2Ab2 Cry1Ac DMO CP4 EPSPS
Dairy cattle 2,770 43 769 138 2,077
31 Dossier: Part II – Sections 5 and 6.
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3.7.1. Persistence and invasiveness of the GM plant
Cultivated soybean (Glycine max (L.) Merr.) is a species in the subgenus Soja of the genus Glycine.
The species originated from eastern Asia and is a highly domesticated crop, generally unable to survive
in the environment without appropriate management (Lu, 2005).
Occasional feral GM soybean plants may occur outside cultivation areas, but survival is limited
mainly by a combination of low competitiveness, absence of a dormancy phase and susceptibility to
plant pathogens and cold climatic conditions (OECD, 2000). Soybean can grow as volunteers and the
presence of volunteers of G. max was occasionally reported in some areas of Italy where soybean is
intensively cultivated (Celesti-Grapow et al., 2010). However, as for the same reasons mentioned
above, soybean seeds usually do not survive during the winter (Owen, 2005).
Thus, the establishment and survival of feral and volunteer soybean in the EU is currently limited
and transient.
It is unlikely that the intended traits of soybean MON 87751 9 MON 87701 9 MON 87708 9
MON 89788 will provide a selective advantage to soybean plants, except when they are exposed to
dicamba- and/or glyphosate-containing herbicides or infested by insect pests that are susceptible to
the Cry1A.105, Cry2Ab2 and/or Cry1Ac proteins. However, this fitness advantage will not allow the GM
plant to overcome other biological and abiotic factors (described above). Therefore, the presence of
the intended traits will not affect the persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that soybean MON 87751 9 MON 87701 9
MON 87708 9 MON 89788 will differ from conventional soybean hybrid varieties in its ability to survive
until subsequent seasons, or to establish occasional feral plants under European environmental
conditions in case of accidental release into the environment of viable soybean MON 87751 9
MON 87701 9 MON 87708 9 MON 89788 seeds.
3.7.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA or through vertical gene flow via cross-pollination from feral
plants originating from spilled seeds.
3.7.2.1. Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel Scientific Opinions for the single events (see Table 1). This assessment included
consideration of homology-based recombination processes, as well as non-homologous end joining and
microhomology-mediated end joining. Possible fitness advantages that the bacteria in the receiving
environments would gain from acquiring recombinant DNA were considered. No concern was identified
in regard to an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut
of domesticated animals and humans fed GM material or other receiving environments.
The applicant submitted an updated bioinformatic analysis for each of the single events to assess
possibility for HGT by homologous recombination.
The updated bioinformatic analysis of events MON 87751, MON 87708 and MON 89788 does not
reveal any new DNA sequence that could provide sufficient length and identity which could facilitate
HGT by double homologous recombination, confirming the conclusions of the previous GMO
Panel Scientific Opinions (EFSA GMO Panel, 2018a, 2019a).
The updated bioinformatic analysis for event MON 87701 reveals one DNA sequence at the left
border with sufficient length and identity with bacterial genes from the A. tumefaciens Ti plasmid.
However, there is no indication for facilitated HGT from MON 87701 to bacteria by double homologous
recombination.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage, are not
identified.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this four-event stack soybean to bacteria does not raise any environmental
safety concern.
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3.7.2.2. Plant-to-plant gene transfer
The potential for occasional feral soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788
plants originating from seed import spills to transfer recombinant DNA to sexually compatible plants
and the environmental consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM soybean seeds need to germinate and
develop into plants in areas containing sympatric wild relatives and/or cultivated soybean with
synchronous flowering and environmental conditions favouring cross-pollination. It must be noted that
most soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 seeds are processed in the
countries of production or in ports of importation.
Vertical gene transfer from soybean (G. max) is limited to the species of the subgenus Soja to
which G. max belongs to, as well as the wild relatives G. soja and G. gracilis. Although wild relatives
exist elsewhere, no wild relatives of the subgenus Soja have been reported in Europe so far (Dorokhov
et al., 2004; Lu, 2005). Therefore, vertical gene transfer from GM soybean is restricted to cultivated
soybean (G. max).
Soybean is an annual, almost completely self-pollinating crop with a percentage of cross-pollination
usually below 1% (OECD, 2000; Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007),
although natural cross-pollination rates can fluctuate significantly among different soybean varieties
under particular environmental conditions, such as favourable climate for pollination and an abundance
of pollinators (Caviness, 1966; Gumisiriza and Rubaihayo, 1978; Kikuchi et al., 1993; Ahrent and
Caviness, 1994; Ray et al., 2003; Lu, 2005).
The potential of spilled soybean seeds to establish, grow and produce pollen is extremely low and
transient (see Section 3.7.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM soybean plants resulting from seed spillage, and weedy or cultivated soybean
plants is also considered extremely low. Even if cross-pollination would occur, the GMO Panel is of the
opinion that the likelihood of environmental effects as a consequence of the spread of genes from
occasional feral GM soybean plants in Europe will not differ from that of conventional soybean varieties
for the reasons given in Section 3.7.1, even after exposure to dicamba- and/or glyphosate-containing
herbicides or infestation by insect pests that are susceptible to the Cry1A.105, Cry2Ab2 and/or Cry1Ac
proteins.
3.7.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2016-128 into account (no cultivation), potential
interactions of occasional feral soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788
plants arising from seed import spills with the target organism are not considered a relevant issue.
3.7.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM seeds or occasional feral
GM soybean plants arising from spilled GM seeds is limited, and because ingested proteins are
degraded before entering the environment through faecal material of animals fed GM soybean,
potential interactions of the GM plant with non-target organisms are not considered by the GMO
Panel to raise any environmental safety concern. Interactions that may occur between the Cry proteins
will not alter this conclusion.
3.7.5. Interactions with the abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled seeds or occasional feral soybean
MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 plants arising from seed import spills is
limited, and because ingested proteins are degraded before entering the environment through faecal
material of animals fed GM soybean, potential interactions with the abiotic environment and
biogeochemical cycles are not considered by the GMO Panel to raise any environmental safety concern.
3.7.6. Conclusion on the environmental risk assessment
The GMO Panel concludes that it is unlikely that soybean MON 87751 9 MON 87701 9
MON 87708 9 MON 89788 would differ from conventional soybean varieties in its ability to persist
under European environmental conditions. Considering the scope of application EFSA-GMO-NL-2016-
128, interactions of occasional feral soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788
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plants with the biotic and abiotic environment are not considered to be relevant issues. The analysis of
HGT from soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 to bacteria does not
indicate a safety concern. Therefore, considering the combined traits and their interactions, the
outcome of the comparative analysis and the routes and levels of exposure, the GMO Panel concludes
that soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 would not raise safety
concerns in the event of accidental release of viable GM soybean seeds into the environment.
3.8. Post-market monitoring
3.8.1. Post-market monitoring of GM food/feed
The GMO Panel concluded that soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788,
as described in this application, is nutritionally equivalent to and as safe as the non-GM comparator
and the non-GM soybean reference varieties tested (Section 3.6.7). Furthermore, the overall intake or
exposure is not expected to change because of the introduction of the four-event stack soybean into
the market. Therefore, no post-market monitoring (EFSA GMO Panel, 2011a) of food/feed from the
four-event stack soybean is considered necessary.
3.8.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are: (1) to confirm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) to identify the
occurrence of adverse effects of the GMO, or its use, on human health or the environment that were
not anticipated in the ERA.
Monitoring is related to risk management, and thus, a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from soybean MON 87751 9
MON 87701 9 MON 87708 9 MON 89788, no case-specific monitoring is required.
The PMEM plan proposed by the applicant for soybean MON 87751 9 MON 87701 9
MON 87708 9 MON 89788 includes: (1) the description of a monitoring approach involving operators
(federations involved in import and processing), reporting to the applicant, via a centralised system,
any observed adverse effect(s) of GMOs on human health and the environment; (2) a coordinating
system established by EuropaBio for the collection of information recorded by the various operators;
and (3) the review of relevant scientific publications retrieved from literature searches (Lecoq et al.,
2007; Windels et al., 2008). The applicant proposes to submit a PMEM report on an annual basis and a
final report at the end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788. The
GMO Panel agrees with the reporting intervals proposed by the applicant in its PMEM plan.
In the context of annual PMEM reports, the applicant could further improve future literature
searches according to the GMO Panel recommendations given in Section 3.3.
3.8.3. Conclusion on post-market monitoring
No post-market monitoring of food and feed is necessary. The scope of the PMEM plan provided by
the applicant and the reporting intervals are in line with the intended uses of soybean
MON 87751 9 MON 87701 9 MON 87708 9 MON 89788.
4. Overall conclusions
The GMO Panel was asked to carry out a scientific assessment of soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788 for import, processing and food and feed uses in accordance with
Regulation (EC) No 1829/2003.
No new information on the single soybean events MON 87751, MON 87701, MON 87708 and MON
89788 that would lead to a modification of the original conclusions on their safety were identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological and allergenicity assessments indicate that the
combination of the single soybean events and of the newly expressed proteins in the four-event stack
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soybean does not give rise to food/feed safety and nutritional concerns. The GMO Panel concludes
that the four-event stack soybean, as described in this application, is as safe as and nutritionally
equivalent to the non-GM comparator and the non-GM reference varieties tested.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable seeds from the four-event stack soybean into the environment.
The literature searches did not identify any relevant publications on the four-event stack soybean.
In the context of annual PMEM reports, the applicant could further improve future literature searches
according to the GMO Panel recommendations.
In addition, the GMO Panel considered the additional unpublished studies listed in Appendix B. This
new information does not raise any concern for human and animal health and the environment
regarding the four-event stack soybean.
Given the absence of safety and nutritional concerns for foods and feeds from the four-event stack
soybean, the GMO Panel considers that post-market monitoring of these products is not necessary.
The PMEM plan and reporting intervals are in line with the intended uses of the four-event stack
soybean.
In conclusion, the GMO Panel considers that soybean MON 87751 9 MON 87701 9 MON
87708 9 MON 89788, as described in this application, is as safe as the non-GM comparator and the
tested non-GM reference varieties with respect to potential effects on human and animal health and
the environment.
Documentation as provided to EFSA
• Letter from the Competent Authority of Netherlands received on 23 December 2015
concerning a request for authorisation of the placing on the market of soybean MON
87701 9 MON 87708 9 MON 87751 9 MON 89788 (EFSA-GMO-NL-2016-128) submitted in
accordance with Regulation (EC) No 1829/2003 by Monsanto Europe S.A./N.V.
• Application EFSA-GMO-NL-2016-128 validated by EFSA, 22 August 2016.
• Application stopped due to single event, 23 August 2016.
• Request for supplementary information to the applicant, 04 April 2017.
• Receipt of supplementary information from the applicant, 6 June 2017.
• Receipt of supplementary information from the applicant, 19 June 2017.
• Application restarted following adoption of single event, 20 June 2018.
• Request for supplementary information to the applicant, 20 June 2018.
• Request for supplementary information to the applicant, 18 July 2018.
• Receipt of supplementary information from the applicant, 20 July 2018.
• Receipt of supplementary information from the applicant, 13 August 2018.
• Request for supplementary information to the applicant, 21 September 2018.
• Receipt of supplementary information from the applicant, 03 October 2018.
• Receipt of supplementary information from the applicant, 03 October 2018.
• Request for supplementary information to the applicant, 11 October 2018.
• Receipt of supplementary information from the applicant, 14 November 2018.
• Request for supplementary information to the applicant, 12 December 2018.
• Receipt of supplementary information from the applicant, 29 January 2019.
• Request for supplementary information to the applicant, 5 February 2019.
• Receipt of supplementary information from the applicant, 25 February 2019.
• Request for supplementary information to the applicant, 11 April 2019.
• Receipt of supplementary information from the applicant, 06 May 2019.
• Receipt of supplementary information from the applicant, 08 May 2019.
• Receipt of supplementary information from the applicant, 17 May 2019.
• Receipt of supplementary information from the applicant, 4 June 2019.
• Request for supplementary information to the applicant, 14 June 2019.
• Receipt of supplementary information from the applicant, 19 June 2019.
• Receipt of supplementary information from the applicant, 7 August 2019.
• Receipt of spontaneous information from the applicant, 19 August 2019.
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Abbreviations
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
GM genetically modified
GMO genetically modified organism
GMO Panel EFSA Panel on Genetically Modified Organisms
HGT horizontal gene transfer
HR homologous recombination
IgE immunoglobulin E
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PCR polymerase chain reaction
PMEM post-market environmental monitoring
UTR untranslated region
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Appendix A – Protein expression data
Mean, standard deviation and range of protein levels (lg/g dry weight) from soybean MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 (treated with dicamba and glyphosate), MON
87751 (not treated), MON 87701 (not treated), MON 87708 (treated with dicamba), MON 89788
(treated with glyphosate) from a field trial performed across five locations in USA in 2013 (n = 20).
Protein Event(s) Leaf (V3-V4)
Leaf
(V4-V7)
Leaf
(R2-R3)
Leaf (R6) Root (R6)
Forage
(R6)
Seed (R8)
Cry1A.105 MON
87751 9
MON
87701 9
MON
87708 9
MON
89788
480(a)  190(b)
(140–830)(c)
250  190
(72–650)
630  320
(230–1,300)
1,400  490
(730–2,600)
< LOQ  N/A 360  170
(110–790)
3.7  0.94
(2.3–5.7)
MON
87751
300  160
(51–660)
280  150
(73–690)
420  180
(110–830)
1,800  840
(870–3,700)
< LOQ  N/A 400  170
(83–780)
4.0  1.3
(2.3–7.4)
Cry2Ab2 MON
87751 9
MON
87701 9
MON
87708 9
MON
89788
9.8  4.7
(2.5–17)
19  6.4
7.6–30)
22  5.0
(12–31)
13  2.3
(8.8–18)
7.7  2.9
(4.4–17)
5.6  1.0
(3.4–7.5)
2.7  1.1
(1.2–5.0)
MON
87751
12  5.0
(4.7–21)
18  6.2
(8.4–29)
17  3.9
(9.4–22)
13  5.1
(8.0–23)
6.6  2.2
(3.9–12)
5.4  1.4
(3.3–8.2)
2.2  0.85
(1.3–4.7)
Cry1Ac MON
87751 9
MON
87701 9
MON
87708 9
MON
89788
300  120
(88–500)
250  110
(100–510)
570  140
(360–800)
2,100  960
(920–4,800)
< LOQ  N/A 100  37
(52–190)
7.7  1.5
(5.9–12)
MON
87701
240  98
(91–390)
510  210
(230–950)
560  160
(300–820)
1,800  500
(1,100–
3,000)
< LOQ  N/A 210  160
(94–700)
7.0  1.1
(5.1–9.9)
DMO MON
87751 9
MON
87701 9
MON
87708 9
MON
89788
21  13
(6.3–48)
12  7.1
(4.1–30)
15  4.8
(7.1–26)
23  21
(8.3–110)
4.0  3.7
(0.72–16)
18  4.0
(13–28)
13  3.8
(7.7–20)
MON
87708
14  7.6
(5.4–30)
12  6.3
(3.3–25)
26  14
(11–69)
30  13
(17–78)
1.3  0.47
(0.44–2.2)
19  7.2
(11–37)
30  5.5
(23–43)
CP4 EPSPS MON
87751 9
MON
87701 9
MON
87708 9
MON
89788
310  190
(130–850)
370  97
(230–580)
460  120
(250–700)
320  65
(220–500)
22  11
(7.2–42)
270  120
(110–510)
100  35
(54–190)
MON
89788
270  150
(71–600)
240  83
(140–430)
430  120
(270–720)
260  97
(170–440)
64  30
(30–130)
220  80
(110–380)
180  26
(140–230)
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DMO: dicamba mono-oxygenase; EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase.
(a): Mean.
(b): Standard deviation.
(c): Range.
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Appendix B – List of additional unpublished studies performed by or on
behalf of the applicant with regard to the evaluation of the safety of the
food and feed for humans, animal and the environment for soybean MON
87751 3 MON 87701 3 MON 87708 3 MON 89788
Study
identification
Title
CRO-2013-0142 An Acute Toxicity Study of E. coli-produced Cry1A.105 protein by Oral Gavage in Mice
MSL0022885 Immunodetection of Cry1Ac Following Heat Treatment
MSL0023031 The Effect of Heat Treatment on Dicamba Mono-Oxygenase (DMO) Enzyme Immunodetection
MSL0023754 Amended Report for MSL0022565: Effect of Temperature Treatment on the Functional Activity
of Cry1Ac
MSL0026197 An Acute Toxicity Study of E. coli-produced MON 87708 DMO protein by Oral Gavage in Mice
MSL0026236 Amended report for MSL0026192: summary of acute toxicity studies of E. coli-produced
Cry2Ab2 protein by oral gavage in mice
MSL0026332 Southern blot analyses to confirm the presence of MON 87751, MON 87701, MON 87708 and
MON 89788 in the combined trait soybean product MON 87751 9 MON 87701 9 MON
87708 9 MON 89788
MSL0026454 An acute toxicity study of E. coli-produced CP4 EPSPS protein by oral gavage in mice
MSL0026673 Comparison of broiler performance and carcass parameters when fed diets containing MON
87751 9 MON 87701 9 MON 87708 9 MON 89788, control or reference soybean meal
MSL0026776 An acute oral gavage toxicity study of E. coli-produced MON 87708 DMO protein in CD-1 mice
MSL0026884 Amended Report for MSL0026036: Phenotypic Evaluation of Soybean MON 87751 9 MON
87701 9 MON 87708 9 MON 89788 with Herbicide Treatments in 2013 U.S. Field Trials
MSL0026885 Amended report for MSL0026363: phenotypic evaluation and environmental interactions of
soybean MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 in 2013 U.S. field trials
MSL0026935 Amended report for MSL0025737: compositional analyses of soybean seed and forage from
MON 87751 9 MON 87701 9 MON 87708 9 MON 89788 grown in the United States in 2013
MSL0026971 Comparison of Gly m 4 expression levels from MON 87751 9 MON 87701 9MON 89788, MON
87751 9 MON 87701 9 MON 87708 9 MON 89788 and conventional soybeans
MSL0027230 Assessment of Cry1A.105, Cry2Ab2, Cry1Ac, DMO and CP4 EPSPS Protein Levels in Soybean
Tissues Collected from MON 87751 9 MON 87701 9 MON 87708 9 MON 89788, MON 87751,
MON 87701, MON 87708 and MON 89788 Produced in Brazilian Field Trials During 2014/2015
growing season
SCR-2014-0210 Compositional analyses of soybean seed and forage from MON 87751 9 MON 87701 9 MON
87708 9 MON 89788 grown in the United States in 2013
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